Urinary Tract Infection (UTI) Pathogen Panel with Antibiotic Resistance, Molecular
Urinary tract infection (UTI) is a common bacterial infection affecting both men and women. UTIs are classified as ‘upper urinary tract infections’ when they involve the kidney, renal pelvis or ureter and ‘lower urinary tract infection’ when only the bladder or urethra is involved. Specific diagnosis is based on organs infected such as cystitis, (urinary bladder), urethritis (urethra), and pyelonephritis (kidney).
UTIs may also be defined based on severity or other factors as ‘uncomplicated’ and ‘complicated’. Uncomplicated UTIs are typically seen in healthy people, who have no medical problems or urinary tract abnormalities. Complicated UTIs are often associated with people who have chronic medical problems, immunocompromised patients and patients with urinary tract structural problems including urinary obstruction, renal failure, renal transplantation, pregnancy and the presence of foreign bodies such as calculi, indwelling catheters or other drains.
Timely and accurate identification and determination of the antimicrobial susceptibility of uropathogens is central to the management of UTIs. Currently, most UTI’s are diagnosed by urinalysis and reflexed culture with sensitivity testing, however, this may take 3-4 days for final results. In addition, culture might not always detect co-infection of 2 or more pathogens (isolates), which may lead to treatment failures. Detection of most common UTI pathogens directly from urine by molecular methods can solve these issues. This technology has the capability to detect and report pathogens and antibiotic resistance genes within hours providing the necessary information for prompt diagnosis and treatment.
Diagnostic testing for antibiotic resistance has historically been culture-based, where susceptibility is performed in conjunction with identification. The main disadvantage of culture based antibiotic resistance which also is considered as phenotyping, is the time to perform the testing. Depending on the microorganism, it might take 3-4 days to get results out; usually it takes couple days to grow bacteria and then to perform susceptibility testing. Another disadvantage of culture-based methods is multiple organisms or co-growth, where specimen contains more than one microbe. This might become difficult to pinpoint what is causing the infection and what may have been living on the plate. Obtaining a pure culture is critical to accuracy in identifying and looking for antibiotic resistance susceptibility.
Since accurate and timely detection of antibiotic-resistance patterns are crucial for the timing and right antibiotic selection for the treatment of infection, new techniques such as molecular have become more adaptive and better for antibiotic detection. Antibiotic resistance testing by molecular or polymerase chain reaction (PCR), which belongs to genotyping tests, is currently the best approach to screen for multi drug resistance organisms. The main advantage of molecular tests is that they identify specific resistance mechanisms within the same day. These tools allow clinicians to make better informed decisions more quickly—and deliver the most effective antibiotic to the patient.
Most panels will detect the common gram negative, gram positive bacterial and yeast pathogens associated with UTI and antibiotic resistance genes associated with tested bacterial pathogens. Results from detected pathogens and antibiotic resistance genes will give suggestions on drug classes or drugs used for UTI treatment.
As with all molecular tests, the UTI molecular panel will only detect pathogens and resistance genes it is designed to detect. It may therefore give false negative results with uncommon pathogens or may not detect organisms that possess unusual resistance mechanisms. For this reason, cultures are often initiated at the time of molecular testing to confirm and or clarify the panel results. Further, due to the sensitivity of molecular methods they may give false positive results due to small numbers of common bacteria or contaminants that are not actually causing clinical infection.
- Diagnosis of urinary tract infection
- Treatment monitoring and disease management
- Detection of any of the organisms above is considered a positive result and should be follow by susceptibility testing or antibiotic resistance gene testing.
- Most assays will report qualitative results as “Detected or Not Detected” in conjunction with semi-quantitative, reporting of genomic copy numbers detected (CFU/mL).
- Pathogens above 100,000 copies will be reported as “Detected” accompanied with a semi-quantitative reporting as >100,000 CFU.
- Results will be also reported as “Detected” if pathogens are detected in greater than 10,000 copies. In this case, results will be reported in numbers (e.g. 35,000).
- Furthermore, if any pathogen is detected < 10,000 copies it will also be reported as “Detected” and will be accompanied with the footnote: “Although reported counts less than 10,000 CFU/mL is usually not clinically relevant and often indicates contamination, some organisms in lower concentration can still be pathogenic and cause infection”.
- The results will be reported as “Not Detected” when no concentration or pathogen is not present.
- Detected antibiotic resistance genes will be also reported as "Detected and Not Detected".
- Some methodologies based on detected bacterial pathogens and antibiotic resistance genes can recommend drug classes or drugs for treatment.
Not Detected (Negative)
Clean catch, midstream urine collected in sterile cup, or urine vacutainer tube, or collected in urine collection tube with preservatives (boric acid) to inhibit bacterial overgrow.
Stability
- Room: up to 4 hours
- Refrigerated: up 72 hours if collected with preservatives
- PLoS One. 2013 Apr 23;8(4):e61439. [PMID: 23626685]
- Clin Microbiol Infect. 2017 Sep;23(9):647-652. [PMID: 28457846]
- PLoS One. 2016 Mar 8;11(3):e0150755. [PMID: 26954694]
- Clin Infect Dis. 2013 Aug;57(4):e22-e121. [PMID: 23845951]
- J Microbiol Methods. 2018 Mar;146:92-99. [PMID: 29427686]
- Am J Med. 2002 Jul 8;113 Suppl 1A:14S-19S. [PMID: 12113867